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Abstract
Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and
obesity. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts
neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake,
and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the
change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with
Alzheimer’s disease compared to those who are receiving placebo.
Methods/design: ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of
liraglutide in participants with mild Alzheimer’s dementia. A total of 206 participants will be randomised to receive
either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral
glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from
baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are
the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer’s Disease
Assessment Scale—Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical
Dementia Rating Sum of Boxes, and Alzheimer’s Disease Cooperative Study—Activities of Daily Living) and the
incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments.
Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging
parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change
in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite
scores using support machine vector analysis in the treatment group compared with the placebo group.
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Discussion: Alzheimer’s disease is a leading cause of morbidity worldwide. As available treatments are only symptomatic,
the search for disease-modifying therapies is a priority. If the ELAD trial is successful, liraglutide and GLP-1 analogues will
represent an important class of compounds to be further evaluated in clinical trials for Alzheimer’s treatment.
Trial registration: ClinicalTrials.gov, NCT01843075. Registration 30 April 2013.
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Background
Alzheimer’s disease (AD) is a devastating progressive neu-
rodegenerative disease and the most common form of de-
mentia, affecting 10% of people over 65 years old and 40%
of those over 85 years old. It is a major global healthcare
burden. In 2015, an estimated 46.8 million people world-
wide were living with dementia and the estimated global
cost of dementia was US$818 billion [1]. The therapeutic
options currently available only include symptomatic
drugs that do not stop disease progression. There are no
treatments available to slow disease progression or to pre-
vent cognitive and functional deterioration. The identifica-
tion of a safe and effective disease-modifying therapy is
thus a key research priority [2].
There is compelling evidence that GLP-1 analogues
exert influence on AD pathology by multiple mecha-
nisms [3]. Given the urgent need for an effective treat-
ment, we propose a phase IIb study to generate safety
and efficacy data in people with AD for liraglutide. This
compound is already licensed for treating type 2 diabetes
mellitus and has shown promising results in a mouse
model of AD and in a small group of AD participants
[4]. If successful, this trial will highlight the importance
of a definitive phase III trial to establish the efficacy of
the compound in people with AD.
The rationale for using an antidiabetic drug in AD is
based on the multiple pathophysiological connections that
have been established between type 2 diabetes mellitus
and AD. Type 2 diabetes has been identified as a risk fac-
tor for AD [5]. Insulin signalling is impaired in type 2 dia-
betes mellitus and is desensitised in AD brains [6]. Apart
from controlling blood glucose, insulin has the general
physiological profile of a growth factor. Neuronal insulin
receptors can induce dendritic sprouting, neuronal stem
cell activation, general cell growth, and repair [7–12]. In-
sulin and the related insulin-like growth factor (IGF-1) are
both potent neuroprotective factors and regulate levels of
phosphorylated tau [13, 14]. Insulin improves brain func-
tion such as attention, memory, and cognition in humans
[15–18]. Nasal application of insulin, which allows it to
enter the brain more directly than other application
routes, has clear effects on attention and memory forma-
tion [17, 19, 20] but may be associated with risks, like in-
advertent bouts of hypoglycaemia.
Moreover, a recent network meta-analysis has shown
that, overall, antidiabetic agents significantly improved
cognition in subjects with AD and mild cognitive im-
pairment, indicating a pro-cognitive class effect of anti-
diabetic agents in these diseases [21].
However, it is conceivable that GLP-1 analogues can
influence AD pathogenic mechanisms through pathways
specifically related to the pharmacodynamics of the
GLP-1 analogues, even in non-diabetic patients.
Among GLP-1 analogues, liraglutide is currently ap-
proved for treatment in type 2 diabetes and obesity in
the EU and other countries. In diabetes, it has shown to
be effective in glycaemic control, both as a monotherapy
and in combination with other antidiabetic drugs, and to
reduce cardiovascular risk [22, 23]. Its safety profile has
been evaluated in different clinical trials and the most
frequently reported adverse reactions during clinical
trials were gastrointestinal disorders (nausea and
diarrhoea) [24].
Glucagon-like peptide-1 in the brain
Insulin is not the only glucostatic hormone that can act
as a growth factor in the brain. Several parallel signalling
systems also modulate blood glucose levels, such as the
incretin hormone signalling pathways [25]. For example,
glucagon-like peptide-1 (GLP-1) is an incretin hormone
that binds to GLP-1 receptors mainly expressed on pan-
creatic beta-cells and the gastrointestinal system, which
are G-protein coupled receptors [26].
GLP-1 receptors are also found in the brain [27–29].
Similar to insulin, GLP-1 in the brain is principally a
growth factor that increases cell growth, proliferation,
and repair and inhibits apoptosis [30]. It induces neurite
outgrowth and protects against excitotoxic cell death
and oxidative injury in cultured neuronal cells [31, 32].
In one study, neurons were protected against cell death
induced by β-amyloid 1–42, and against oxidative stress
and membrane lipid peroxidation caused by iron [27].
Mice that overexpress GLP-1 receptors in the hippocam-
pus show increased neurite growth and improved spatial
learning abilities [33].
Both the native peptide GLP-1 and long-lasting ana-
logues such as extendin-4, Val(8)GLP-1, and liraglutide
can cross the blood–brain barrier [26–29]. These
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analogues not only cross the blood–brain barrier after
peripheral injection, but also show physiological effects
in the brain by increasing neuronal progenitor prolifera-
tion, enhancing long-term potentiation in the hippocam-
pus, improving learning, reducing plaque formation and
inflammation in the brain, and even increasing neuro-
neogenesis [34].
GLP-1 analogues have neuroprotective effects in mouse
models of AD. For example, one study gave chronic intra-
peritoneal injections of Val(8)GLP-1 for 3 weeks to a
mouse model of AD that overexpressed the human Swed-
ish mutated form of amyloid precursor protein (APP) and
a human mutated form of presenelin-1 (PS1). The mice
retained synaptic plasticity in their hippocampi, loss of
which is an effect of plaque formation [35].
In another APP/PS1 mouse model of AD, liraglutide
showed a range of protective effects when injected daily
for 8 weeks at a dose comparable to that received by pa-
tients with diabetes. The key hallmarks of AD and neu-
rodegeneration were reversed or improved, including
β-amyloid synthesis, plaque formation, inflammation in
the brain, synaptic loss, and memory impairment [36].
In different mouse models of diabetes, neuronal pro-
genitor cell proliferation in the dentate gyrus was en-
hanced, and the number of young neurons in the
dentate gyrus increased with systemic administration of
both exenatide and liraglutide, indicating that additional
repair processes had been activated in the brain [37, 38].
Insulin signalling was found to be desensitised in an
ex vivo study of human brain tissue from AD patients.
Liraglutide was able to reverse key biomarkers of insulin
signalling desensitisation, such as the phosphorylation of
insulin receptor β-chain IRβ pY1162/1163 and IRS-1 phos-
phorylation at S616 [39].
Together, these effects show a substantial reduction in key
symptoms and hallmarks of AD in the presence of GLP-1
analogues. These analogues can cross the blood–brain bar-
rier and do not affect blood glucose levels in normogly-
caemic people [40]. As the GLP-1 analogue liraglutide has
already been established on the market and shows few side
effects, it is a promising AD treatment candidate.
A pilot clinical trial compared 18 AD participants
treated with liraglutide with 20 AD participants treated
with placebo. Six months of treatment with this GLP-1
analogue prevented decline of brain glucose metabolism,
although no significant cognitive changes were observed,
compared with the placebo group [4].
The primary objective of the ELAD trial is to evaluate
the change in cerebral glucose metabolic rate after 12
months of treatment with liraglutide compared to the
placebo. Secondary objectives include the evaluation of
change in cognitive measures, MRI changes, microglial
activation, amyloid and tau changes, and the incidence
and severity of treatment-emergent adverse events.
Methods and design
Study design
ELAD is a 12-month, multi-centre, randomised,
double-blind, placebo-controlled, phase IIb trial in par-
ticipants with very mild AD dementia. Eligible partici-
pants will be randomised on a 1:1 ratio to receive
liraglutide (1.8 mg) or matching placebo. A total of 206
participants will be recruited from sites across the UK,
from local Memory Clinics and national databases, like
“Join dementia research” (www.joindementiaresearch.
nihr.ac.uk) All participants will start with a dose of 0.6
mg, and the dose will be escalated to 1.8 mg within 4
weeks. Participants who do not tolerate 1.8 mg will stay
on 1.2 mg for an extra 2 weeks, and then two more at-
tempts will be made to increase the dose to 1.8 mg. If
1.8 mg is still not tolerated, the participants will remain
on 1.2 mg throughout the remainder of the trial.
Outcome measures
Outcome measures in the ELAD trial include both bio-
markers and clinical measure changes from baseline to
follow up.
The primary outcome of the ELAD trial is as follows:
– The change in cerebral glucose metabolic rate in the
cortical regions (hippocampal, medial temporal lobe,
and posterior cingulate) from baseline to follow-up
(12 months) in the treatment group, compared with
the placebo group. This will be measured using
[18F]fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) at baseline and at 12 months.
Secondary outcomes are as follows:
– The change in cognitive and functional abilities from
baseline to 12 months, measured as changes of z
scores for the Alzheimer’s Disease Assessment
Scale—Cognitive Subscale and Executive domain
scores of the Neuropsychological Test Battery
(ADAS Exec), Clinical Dementia Rating Sum of
Boxes (CDR-SoB), and Alzheimer’s Disease
Cooperative Study—Activities Of Daily Living
(ADCS-ADL) in the treatment group, compared
with the placebo group [41–43].
– The incidence and severity of treatment-emergent
adverse events or clinically important changes in
safety assessments over 12 months.
– The changes in structural imaging measures,
evaluated by entorhinal cortex and hippocampal
volume, diffusion tensor imaging spectra, and
magnetic resonance (MR) spectra from baseline to
12 months in the treatment group, compared with
the placebo group.
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– Establishing whether there is a reduction in
microglial activation in subjects with mild AD
following daily subcutaneous injection of liraglutide
for 1 year, using translocator protein positron
emission tomography (TSPO PET) scanning,
compared with subjects receiving placebo injections,
in a subgroup of participants.
– The change in the hippocampal, entorhinal, and
other cortical regions’ tau deposition in the
treatment group, compared to the placebo group, in
a different subgroup of participants using tau PET.
– The changes in levels of cortical amyloid load in the
treatment group, compared with the placebo group,
in the same subgroup as the tau PET substudy.
– The change from baseline to 12 months in the
composite score created using the support vector
machine algorithm derived from cognitive tests,
changes in MR imaging (MRI)-derived numerical
summaries (hippocampal, temporal, and ventricular
volume), changes in [18F]FDG-PET, Apolipoprotein
E4 (ApoE4) status, and age.
The pharmacodynamics outcome is as follows:
– Plasma markers of neuroinflammation
(proinflammatory and anti-inflammatory cytokines:
IL-6, TNF-α, IL-8, IL-10, IL-12, CRP, TGF-β).
Eligibility criteria
Inclusion and exclusion criteria are presented in Table 1.
Study medication
Liraglutide, at doses up to 1.8 mg, has been approved in
several countries, including the EU, Japan, Australia, and
the USA, for the treatment of type 2 diabetes under the
trade name Victoza®. In March 2015, the European Med-
icines Agency approved its use in obesity under the
trade name Saxenda®, at doses up to 3 mg. The doses
used in the ELAD trial are those approved for diabetes,
as at the time of the study design liraglutide was only
approved for clinical use in diabetes.
Pharmacokinetic data from the clinical development
programme for liraglutide demonstrated that it is
absorbed slowly (tmax = 8–12 h) and has a half-life of ap-
proximately 13 h. Liraglutide is thus suitable for
once-daily subcutaneous injection given any time of the
day, independent of meals [44].
Investigation of liraglutide metabolism in vitro and in
healthy subjects has indicated that liraglutide is en-
dogenously metabolised and that neither renal excretion
nor hepatic extraction are major routes of clearance.
The pharmacokinetics of liraglutide has been investi-
gated in human subjects with renal and hepatic impair-
ment and has not raised any safety concerns. However,
the therapeutic experience in subjects with hepatic or
renal impairment is limited. The effects of age and gen-
der on the pharmacokinetics of liraglutide have been in-
vestigated, and it was concluded that all participants,
regardless of age or gender, should be dosed in accord-
ance with the usual proposed dose regimen for liraglu-
tide [45].
In the ELAD trial, participants will start with a dose of
0.6 mg liraglutide by subcutaneous injection into the ab-
domen, thigh, or upper arm. The dose will be escalated
in weekly steps of 0.6 mg up to 1.8 mg once daily, if tol-
erated. Participants can stay on 1.2 mg if this is the max-
imum tolerated dose.
The study medication will be provided as prefilled pens
so that the active treatment and placebo cannot be identi-
fied, guaranteeing that the study remains double-blinded.
At the beginning of the study, the study drug will be ad-
ministered subcutaneously under supervision. Participants
and caregivers will be instructed in the administration and
correct storage and handling of the pens.
Medication will be dispensed at weeks 0, 8, 16, 24, 32,
40, and 48 by each trial centre.
Sample size
Landau et al. [46] used the [18F]FDG-PET imaging bio-
marker to monitor the progression of AD. At and after
12 months, they found a mean change in the [18F]FDG
region of interest (ROI) of − 0.055, with an SD of 0.068.
Assuming that the treatment reduces the mean change
in the AD participants to − 0.025 (44% effect size), 82
participants are required per group to provide 80%
power at a 5% significance level. Allowing for a drop-out
of 15% over the study period, the trial requires 103 par-
ticipants per group (206 in total).
Trial conduct
Study assessments
All participants will undergo the evaluations outlined
in Fig. 1. Each visit during the double-blind phase
will take place on the last day (± 4 days) of the study
week. The week 16 (W16), week 28 (W28), week 36
(W36), and week 44(W44) visits will be a telephone
call to check for any adverse events, with a follow-up
visit at the study centre if needed. At the week 52
(W52) visit, final efficacy and safety assessments will
be carried out and unused study medication will be
collected. Four weeks after the end of the study, a
final follow-up phone call will be made (W56). The
clinical assessments will be done by a trained research
nurse and a trained research doctor, when indicated.
The neuropsychological assessments will be done by a
trained rater at the research sites.
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Randomisation
Participants will be randomised to receive active drug or
placebo with a 1:1 allocation ratio using stratified block
randomisation with a fixed block size. The stratification
factors are age and the Mini Mental State Examination.
Randomisation will take place using an interactive voice
response system. Mawdsleys [47] is the contractor re-
sponsible for randomising the ELAD participants and
storing and distributing the drug. Figure 1 presents the
schedule of enrolment for the trial.
Table 1 ELAD trial inclusion and exclusion criteria
Inclusion criteria
1. Capable of giving and capacity to give informed consent
2. An individual who can act as a reliable study partner with regular
contact (a combination of face-to-face visits and telephone contact is
acceptable) who has sufficient interaction with the participant to
provide meaningful input into rating scales and, if necessary,
supervise or perform the injections, as judged by the investigator
3. Diagnosis of probable AD disease according to National Institute on
Aging–Alzheimer’s Association (NIA-AA) criteria [50] or National
Institute of Neurological and Communicative Disorders and
Stroke–Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria
4. Age from 50 years
5. Mini-Mental State Examination score of ≥ 15 and CDR-Global score of
0.5, 1, or 2 with capacity to consent, and the clinician anticipates that
the participant will have capacity to complete the study
6. Rosen Modified Hachinski Ischemic score≤ 4
7. On stable medication for 2 months before the screening visit; on or
off cholinesterase inhibitors
8. Fluency in English and evidence of adequate premorbid intellectual
functioning
9. Likely to be able to participate in all scheduled evaluations and
complete all required tests
Exclusion criteria
1. Patients on treatment for diabetes mellitus
2. Any contraindications to the use of liraglutide as per the summary of
product characteristics (hepatic impairment, renal impairment with
chronic kidney disease stage 4 and above (eGFR < 30ml/min/1.73m2),
or inflammatory bowel disease). Patients with eGFR < 45ml/min/1.73m2
will have their renal function monitored very closely
3. Significant neurological disease other than AD that may affect cognition
4. MRI/CT showing unambiguous aetiological evidence of
cerebrovascular disease with regard to their dementia or vascular
dementia, fulfilling National Institute of Neurological Disorders and
Stroke -Association Internationale pour la Recherche et
l'Enseignement en Neurosciences (NINCDS-AIREN) criteria
5. Current presence of a clinically significant major psychiatric disorder
(e.g., major depressive disorder) according to the criteria of the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV)
6. Current clinically significant systemic illness that is likely to result in
the patient’s condition deteriorating or affect the patient’s safety
during the study
7. History of epilepsy, where seizures or treatment could have
contributed to cognitive impairment
8. Treatment with immunosuppressive medications (e.g., systemic
corticosteroids) within the last 90 days (topical and nasal
corticosteroids and inhaled corticosteroids for asthma are permitted)
or chemotherapeutic agents for malignancy within the last 3 years
9. Myocardial infarction within the last 1 year
10. History of cancer within the last 5 years, except localised skin cancer
11. Other clinically significant abnormalities on physical, neurological, or
laboratory examination that could compromise the study or be
detrimental to the patient
12. History of alcohol or drug dependence or abuse within the last 2 years
13. Current use of anticonvulsant, anti-Parkinson’s disease medication
Table 1 ELAD trial inclusion and exclusion criteria (Continued)
14. Use of experimental medications for AD or any other investigational
medication or device within 60 days. Participants who have been
involved in a monoclonal antibody study are excluded
unless it is known that they were receiving placebo
in that trial
15. Women of childbearing potential
(women who could become pregnant will be required
to use adequate contraception throughout the trial)
16. Patients with a personal or family history of medullary
thyroid carcinoma and patients with multiple endocrine
neoplasia type 2
17. Any contraindications to MRI scanning
AD Alzheimer’s disease, CDR Clinical Dementia Rating, CT computed
tomography, eGFR estimated glomerular filtration rate, MRI magnetic
resonance imaging
Fig. 1 ELAD trial schedule of visits. ADAS-Exec Alzheimer’s Disease
Assessment Scale—Cognitive Subscale and Executive domain scores
of the Neuropsychological Test Battery, ApoE Apolipoprotein, CDR
Clinical Dementia Rating, CT computed tomography, DSM-IV
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
ECG elecrocardiogram, Incl/Excl inclusion/exclusion, MMSE Mini
Mental State Examination, MRI magnetic resonance imaging,
NINCDS-ADRDA National Institute of Neurological and
Communicative Disorders and Stroke–Alzheimer’s Disease and
Related Disorders Association, PET positron emission tomography,
SoB Sum of Boxes, W week
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Withdrawals and unblinding
Participants who drop out of the ELAD study will be re-
corded as either defaulters or withdrawn. Defaulters are
participants who withdraw their consent to participate
in the trial, affecting both treatment and assessment. No
further assessments can be made of these participants.
Withdrawn are participants who are withdrawn from
treatment at the discretion of the chief investigator be-
cause of clinical factors, poor compliance, or a change in
circumstances. Withdrawn participants will remain in
the study and trial assessments will still be undertaken.
The reason for dropping out will also be recorded. In-
vestigators should be able to distinguish between
drop-outs due to dementia-related factors (e.g., cognitive
impairment), treatment-related factors (side effects), and
incidental factors (concurrent physical illness or loss of
study partners). Every effort will be made to collect out-
come data on all participants who withdraw from treat-
ment for whatever reason. If participants withdraw from
treatment, all endpoint assessments should be carried
out at the point of drop-out and at the 12-month end-
point. It may not be possible to complete some assess-
ments with non-compliant participants. However,
assessments will be carried out wherever possible and in
all such cases at the 12-month endpoint.
As ELAD is a double-blind placebo-controlled trial,
the participants, clinicians, statisticians, and chief inves-
tigator will be blinded to each patient’s treatment alloca-
tion. Unblinding will take place when the study has been
completed and the data files have been verified. In a
medical emergency, the designated person from the lead
site at Imperial College, London will be able to break the
randomisation code at the investigators’ request. A par-
ticipant’s treatment assignment will only be unblinded
when knowledge of the treatment is essential for their
further medical management. Unblinding for any other
reason will be considered a protocol violation.
Data management
The ELAD data management plan is consistent with the
MRC Guidelines for Good Clinical Practice in Clinical
Trials (1998).
Clinical data will be entered into paper-based case re-
port forms (CRFs), and then transferred into computers
via Inform version 4.6. The database version is Oracle 10 g
release 10.2.0.4.0 and is supplied by Oracle Corporation.
The data manager will arrange appropriate quality assur-
ance checks.
Participants eligible for study entry will be given a
unique, sequential, centre-specific ELAD study identifier.
After each assessment, data will be entered into CRFs
and the study database at each site. Immediately after
each assessment, the data will be backed up electronic-
ally and securely stored locally. These files will be
backed-up onto a password-protected environment on a
weekly basis. Hard copies will be stored locally, compli-
ant with the Data Protection Act (1998).
Every 2 weeks, data will be sent electronically to the
data management centre at Imperial College London.
Security will be maintained using email to and from
password-protected, networked accounts and will com-
ply with all regulatory requirements. The data manage-
ment centre will merge data across centres and
assessment points.
Adverse events
Safety and tolerability assessments will consist of moni-
toring and recording all adverse events and serious ad-
verse events, and the regular monitoring of vital signs.
Clinically significant abnormalities in vital signs, labora-
tory evaluations, ECG recordings, and physical examina-
tions will be recorded as adverse events and followed up
as appropriate.
As far as possible, each adverse event will be described
by its duration, severity grade, and relationship to the
study drug, the action(s) taken, and, if relevant, the
outcome.
Information about all serious adverse events will be
collected on the ELAD trial. A serious adverse event
is an undesirable sign, symptom, or medical condition
that is fatal or life-threatening, requires hospitalisa-
tion, results in persistent or significant disability/in-
capacity, constitutes a congenital anomaly or birth
defect, or is medically significant. A Suspected Unex-
pected Serious Adverse Reaction (SUSAR) is any ad-
verse reaction that is classed as serious and suspected
to be caused by the investigational medicine product
that is not consistent with the information about it in
the summary of product characteristics (i.e., it is sus-
pected and unexpected). The trial protocol includes a
list of known side effects for the drug in the study. If
the event is not listed as expected or has occurred in
a more serious form than anticipated, this will be
considered a SUSAR. All serious adverse events will
be followed up until the outcome of the event is “re-
covered”, “recovered with sequelae”, or “fatal”, and
until all queries have been resolved. To ensure partic-
ipants’ safety, each serious adverse event will be re-
ported to the data monitoring committee within 24 h
of the trial staff learning of its occurrence.
During each contact with trial site staff (site visits
and telephone contacts), participants will be asked
about adverse events and technical complaints. All
adverse events, either observed by the site investigator
or reported by the participant, will be reported by the
investigator and evaluated by the Principal Investiga-
tor at each site.
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Data analysis
The primary analysis will be based on the modified
intention-to-treat population. Participants will be ana-
lysed according to their allocated treatment group irre-
spective of what treatment they actually received. Patient
throughput for the final analysis will be illustrated using
a CONSORT [48] flow diagram (Fig. 2). Results will be
presented as the adjusted mean difference in the change
in cerebral glucose metabolic rate between randomised
groups at 12 months, with 95% confidence intervals and
associated two-sided p values. A full, detailed analysis
plan will be prepared before the data are unblinded.
Patient demographic characteristics and other baseline
information will be summarised by treatment group.
Numbers (with percentages) for binary and categorical
variables and mean (standard deviation) or median
(interquartile or full range) for continuous variables will
be presented. Differences in the change in FDG-ROI be-
tween randomised groups between baseline and 12
months will be assessed using analysis of covariance,
adjusting for baseline values and stratification factors
used in the randomisation process. The distribution of
the change from baseline will be formally assessed for
evidence of departure from normality. If necessary, data
will be transformed or analysed using a non-parametric
equivalent. The same approach will be used for the sec-
ondary outcomes measured at 12 months only. For out-
comes measured on more than one occasion (e.g.,
ADAS-Exec), a mixed-effect model will be used. The
data will be transformed or non-parametric methods
Fig. 2 Schedule of enrolment
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used if the model assumptions are not met. Adverse
events at 12 months will be analysed using Fisher’s exact
test or the chi-squared test.
Every effort will be made to collect outcome data on
all participants who withdraw from treatment for what-
ever reason. If participants withdraw from treatment,
the endpoint assessments should all be carried out at the
point of drop-out and at the 52-week endpoint. Al-
though it may not be possible to complete some assess-
ments of non-compliant participants, assessments
should be carried out wherever possible and in all such
cases at the 52-week endpoint.
The primary analysis will include all available data, in-
cluding data from withdrawn participants irrespective of
levels of treatment compliance. Assessing outcomes in
participants with different levels of compliance will be
performed as part of the per-protocol analysis with the
per-protocol populations defined in the Statistical Ana-
lysis Plan. No primary analysis will be performed on de-
faulters since by definition they will not have completed
the primary outcome (PET imaging) at 12 months
(modified intention to treat analysis).
All reasons for withdrawing from the study will be
summarised, overall and by arm.
A sensitivity analysis will be carried out on a
per-protocol basis to examine the conclusions’ robust-
ness to different assumptions about departures from the
randomisation procedure. The per-protocol population
is all participants who received the allocated treatment
with no major protocol deviations and who have pro-
vided results at the end of follow-up assessment.
Trial oversight
The chief investigator has overall responsibility for the
conduct of the study. The trial management group has re-
sponsibility for the day-to-day management of the trial.
The trial steering committee, comprising independent
clinicians and an independent statistician, acts as the
oversight body for the trial on behalf of the sponsor.
This committee will take responsibility for monitoring
and guiding overall progress, scientific standards, and
operational delivery and for protecting the rights and
safety of the trial participants, throughout the trial.
An independent data monitoring committee (IDMC)
will undertake ongoing reviews of the study’s safety. The
committee composition, committee responsibilities, and
a schedule for reviewing data have been approved and
signed off by all committee members. The members in-
clude appropriately qualified clinicians and an independ-
ent statistician. The IDMC charter was prepared,
reviewed, and approved ahead of the first committee
meeting. The purpose of the charter is to describe the
IDMC’s membership, terms of reference, roles, responsi-
bilities, authority, decision-making, and relationships for
this trial, including the timing of meetings, methods of
providing information to and from the committee, fre-
quency and format of meetings, statistical issues, and re-
lationships with other committees. No formal interim
analysis has been planned for ELAD, and one will only
be conducted if the IDMC requests it (Additional file 1).
Discussion
AD is a leading cause of disability worldwide. It is esti-
mated that by 2050, 1 in 85 of the global population will
be affected, resulting in a significant social and economic
burden for healthcare systems. As the treatments
currently available are only symptomatic and do not in-
fluence the course of the disease, the search for
disease-modifying treatments is a priority. In the decade
2002–2012, more than 400 trials were performed in AD,
testing 244 compounds. Of those, only memantine was
approved for clinical use in AD, in 2003 [2]. The failure
of the vast majority of anti-amyloid trials in AD suggests
that other pathways should be explored in the search of
an effective disease-modifying therapy.
There is convincing preclinical evidence that liraglutide
has favourable effects on the neurodegenerative process of
AD. Administering liraglutide in preclinical models re-
duces amyloid deposition and neuroinflammation, im-
proves brain glucose metabolism and cognitive outcomes,
and increases the proliferation of neuronal progenitor
cells. Moreover, 6 months of liraglutide treatment in 20
AD participants prevented decline of brain glucose metab-
olism and other studies are investigating the potential for
GLP-1 analogues in neurodegeneration. In this study, the
participants are selected based on clinical diagnosis of AD,
rather than on biomarker status, as suggested by more re-
cent research guidelines [49]. As liraglutide works on mul-
tiple mechanisms, and not specifically on amyloid,
including patients with a clinical diagnosis of AD will
allow us to translate the findings and potential future
treatment to the entire AD population diagnosed clinically
rather than those with biomarker criteria.
Liraglutide is currently approved for the treatment of
type 2 diabetes and obesity, where it shows a good safety
profile and is well tolerated. If the ELAD trial is successful,
liraglutide might represent an advance in the treatment of
AD, to be further evaluated in larger studies, and might
possibly have a positive impact on healthcare systems.
Trial status
Recruitment is ongoing.
Additional file
Additional file 1: SPIRIT 2013 checklist: items addressed in the clinical
trial protocol. (DOC 121 kb)
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